telmisartan + captopril

Telmisartan + captopril is a combination of two antihypertensive agents used together for their complementary effects on the renin-angiotensin-aldosterone system (RAAS). Telmisartan is an angiotensin II receptor blocker (ARB) that selectively blocks the binding of angiotensin II to the AT1 receptor in vascular smooth muscle and adrenal gland, leading to vasodilation and reduced blood pressure. Captopril is an angiotensin-converting enzyme (ACE) inhibitor that prevents the conversion of angiotensin I to angiotensin II, further reducing vasoconstriction and aldosterone-mediated volume expansion. The combination has been studied for its potential additive or synergistic effects in lowering blood pressure and modulating inflammation markers in specific populations such as hemodialysis patients[2][3][6]. Both drugs are approved individually for hypertension, heart failure, diabetic nephropathy, and cardiovascular risk reduction; however, their combined use is not standard due to increased risk of adverse events such as hyperkalemia, hypotension, and renal dysfunction[1][5][7].

Other names

telmisartan and captoprilcaptopril + telmisartan